Aster DM Healthcare board approves FY26 audited results

Board clears audited numbers for Q4 and full year FY26

Aster DM Healthcare Ltd said its Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The decision was taken at a board meeting held on April 30, 2026, as per the company’s filing on BSE. The update puts an official stamp on the company’s reported performance for Q4 and FY26, and completes the annual audit cycle for the year.

The company also disclosed that Deloitte Haskins & Sells, the statutory auditors, issued an unmodified opinion on the audited results. An unmodified opinion indicates the auditors did not qualify the financial statements in their report, based on the information shared in the exchange filing.

Meeting timeline and filing details

The April 30 board meeting began at 10:30 AM and concluded at 03:35 PM. The company stated that the approved results and the auditor’s report have been uploaded to its website. The board outcome was published on April 30, 2026 at 03:58 PM, with BSE cited as the source.

In addition to the outcome, the disclosures also referenced that a board meeting had been scheduled for April 30, 2026 to consider and approve the same audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The final outcome aligns with that stated agenda.

What exactly was approved

Based on the exchange note, the board considered and approved:

• Audited standalone financial results for the quarter ended March 31, 2026
• Audited consolidated financial results for the quarter ended March 31, 2026
• Audited standalone financial results for the year ended March 31, 2026
• Audited consolidated financial results for the year ended March 31, 2026

The filing does not include specific revenue, profit, or margin figures in the text provided. It focuses on the approval of audited results and the audit opinion.

Statutory audit: Deloitte issues an unmodified opinion

Aster DM Healthcare said Deloitte Haskins & Sells issued an unmodified opinion on the audited standalone and consolidated financial results. In practical terms, this is the standard clean audit outcome companies aim for at year-end, as it indicates the auditors did not report a qualification or adverse view in their opinion.

The company’s disclosure links the audit opinion directly to the results approved for the quarter and year ended March 31, 2026. It also said the auditor’s report is available on its website along with the approved results.

Where investors can find the documents

The company stated that the results and the auditor’s report have been uploaded to its website. For shareholders tracking the company’s disclosures, this means the full audited statements and the statutory audit report should be accessible through the company’s investor communication channels, in addition to exchange filings.

The filing itself emphasises the board approval process and the audit opinion, which are typically key compliance elements expected in annual results announcements.

Related governance updates: shareholder resolutions referenced

The material provided also mentions shareholder voting outcomes on key resolutions. These include the appointment of Dr. Mandayapurath Azad Moopen as Executive Director, which was approved with 99.839% (474,009,383 shares in favour). Another resolution to grant loans, guarantees, or securities was approved with 75.567% votes (358,803,458 shares in favour).

Separately, a note on seeking shareholder approval referenced Dr. Mandayapurath Azad Moopen’s appointment as Executive Director from April 15, 2026 to May 28, 2028, and a maximum annual remuneration set at INR 10 crores. The text also mentions an authorization limit for loans, guarantees, or securities, but the amount is shown as “INR 1,5…” and is incomplete in the provided extract, so no full figure is stated here.

Board actions earlier in FY26: interim dividend and record date

Another board outcome referenced in the text is the March 26, 2026 board meeting, where Aster DM Healthcare declared an interim dividend for FY 2025-26. The company also disclosed a record date for payment of interim dividend, if declared, as Friday, April 3, 2026.

While this is separate from the April 30 audited results approval, dividend actions and audited results announcements are often tracked together by investors because they are both board-level decisions communicated through exchange filings.

Earlier corporate disclosures: AGM, appointments, and leadership changes

The extract also includes older corporate updates, including a July 30, 2025 board meeting outcome where Aster DM Healthcare appointed Sudeep Dey as Chief Information Officer and Chief Information Security Officer with effect from August 1, 2025. The company also announced that its 17th Annual General Meeting was scheduled to be held on September 4, 2025.

In the same period, there were disclosures about the resignation of Dr. Devanand K T as Regional CEO for Andhra Pradesh and Telangana and senior management, effective close of business hours on July 19, 2025, and the appointment of Mr. Vineesh Kumar Ghei as Country Head Sales, Marketing and RCM, effective July 10, 2025.

Key facts snapshot

Why this disclosure matters for the market

Board approval of audited financial results is a key compliance milestone, especially for full-year numbers, because it confirms the financial statements have been finalised after audit. The mention of an unmodified audit opinion is also relevant because it indicates the auditors did not flag qualifications in their opinion, as per the company’s statement.

The update also shows the company following standard disclosure practices by uploading the approved results and the auditor’s report to its website. Alongside other referenced governance items such as shareholder voting outcomes, appointments, and dividend-related decisions, the filings provide investors a consolidated view of key corporate actions communicated through BSE.

Conclusion

Aster DM Healthcare’s board approved the audited standalone and consolidated financial results for Q4 and FY26 at its April 30, 2026 meeting, and the company said Deloitte Haskins & Sells issued an unmodified opinion. The company also stated that the approved results and auditor’s report have been uploaded to its website, following the board’s approval process.